Literature DB >> 34676029

Novel Substituted Tetrahydroquinoline Compounds as Indoleamine-2,3-dioxygenase (IDO) Inhibitors.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34676029      PMCID： PMC8521614          DOI： 10.1021/acsmedchemlett.1c00469

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  6 in total

Review 1.  Diverse chemical space of indoleamine-2,3-dioxygenase 1 (Ido1) inhibitors.

Authors:  Rahul Singh; Deepak B Salunke
Journal:  Eur J Med Chem       Date:  2020-12-02       Impact factor: 6.514

Review 2.  The ups, downs and new trends of IDO1 inhibitors.

Authors:  Shulun Chen; Jing Tan; Ao Zhang
Journal:  Bioorg Chem       Date:  2021-03-10       Impact factor: 5.275

Review 3.  Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy.

Authors:  Yixuan Guo; Yu Liu; Wei Wu; Daishun Ling; Qiao Zhang; Peng Zhao; Xi Hu
Journal:  Biomaterials       Date:  2021-07-12       Impact factor: 12.479

Review 4.  Tryptophan metabolism in brain tumors - IDO and beyond.

Authors:  Michael Platten; Mirco Friedrich; Derek A Wainwright; Verena Panitz; Christiane A Opitz
Journal:  Curr Opin Immunol       Date:  2021-04-01       Impact factor: 7.486

Review 5.  Indoleamine and tryptophan 2,3-dioxygenases as important future therapeutic targets.

Authors:  Ana Dolšak; Stanislav Gobec; Matej Sova
Journal:  Pharmacol Ther       Date:  2020-11-16       Impact factor: 12.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.